Company Overview
Snapshot
Founded in June 2021 by Rotem Karni, RNAble operates with 1–10 employees. The company has secured funding across one round from two investors, with Integra Holdings identified as a lead investor. In January 2022, RNAble received seed funding, marking a key early milestone in its development.
Business overview
RNAble is a health tech and life sciences company focused on developing novel compounds that modulate RNA epitranscriptomics. The company's core technology aims to alter RNA stability for the treatment of specific cancers and rare genetic diseases characterized by nonsense mutations. By targeting components of the RNA epitranscriptomic machinery with small molecules, RNAble seeks to stabilize unstable nonsense mutated transcripts, thereby restoring the expression of mutated genes essential for rare diseases and suppressing the growth of specific cancers. RNAble operates within the pharmaceutical and biotechnology sectors, serving the healthcare and life sciences industries.
Log in to access full profile ›Company Intelligence Q&A
- What is RNAble's primary focus?
- RNAble is developing novel compounds designed to alter RNA stability by modulating RNA epitranscriptomics. This approach targets the treatment of specific cancers and rare genetic diseases involving nonsense mutations.
- Who founded RNAble?
- RNAble was co-founded by Rotem Karni, who also serves as an advisor to the company.
- When was RNAble founded?
- RNAble was founded in June 2021.
- Has RNAble received any funding?
- In January 2022, RNAble secured seed funding from Integra Holdings and RMGLOBAL Healthcare Fund Management.
- What markets does RNAble target?
- RNAble targets the pharmaceutical and biotechnology sectors, focusing on applications within healthcare and life sciences, including laboratories and providers.